Willingness to participate in HIV vaccine research in a peri-urban South African community

International Journal of STD and AIDS

Volumn 17, Issue 3, 2006, Pages 176-179

  Smit, J ^a,b   Middelkoop, K ^b   Myer, L ^b,c   Seedat, S ^a   Bekker, L G ^b   Stein, D J ^a,b  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c School of Public Health and Family Medicine   (South Africa)

Author keywords

Clinical trials; HIV prevention; HIV vaccines; Participation; South africa

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESEARCH; EDUCATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEARNING; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATIENT ATTITUDE; PATIENT PARTICIPATION; PRIORITY JOURNAL; SCORING SYSTEM; SOUTH AFRICA; URBAN POPULATION;

AIDS VACCINES; CLINICAL TRIALS; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HIV INFECTIONS; HUMANS; MALE; MOTIVATION; QUESTIONNAIRES; SOUTH AFRICA; SUBURBAN POPULATION;

EID: 33644537337     PISSN: 09564624     EISSN: 09564624     Source Type: Journal    
DOI: 10.1258/095646206775809259     Document Type: Article

References (12)

1. Esparza J, Osmanov S, Pattou-Markovic C, Toure C, Chang ML, Nixon S. Past, present and future of HIV vaccine trials in developing countries. Vaccine 2002;20:1897-8
2. Tucker TJ, Mazithulela G. Development of an AIDS vaccine: perspective from the South African AIDS Vaccine Initiative. BMJ 2004;329:454-6
3. Francis DP, Heyward WL, Popovic V, Orozco-Cronin P, Oreland K, Gee C. Candidate HIV/AIDS vaccines: lessons learned from the world's first phase III efficacy trials. AIDS 2003;17:147-56
4. Temoshok LR. Behavioral research contributions to planning and conducting HIV vaccine efficacy studies. AIDS Res Hum Retroviruses 1994;10:S277-80
5. Grinstead OA. Social and behavioral issues in phase III HIV preventive vaccine trials. AIDS 1995;9:S245-50
6. Chesney MA, Lurie P, Coates TJ. Strategies for addressing the social and behavioral challenges of prophylactic HIV vaccine trials. J Acquir Immune Defic Syndr Hum Retrovirol 1995;9:30-5
7. Koblin BA, Holte S, Lenderking B, Heagerty P. Readiness for HIV vaccine trials: changes in willingness and knowledge among high-risk populations in the HIV network for prevention trials. The HIVNET Vaccine Preparedness Study Protocol Team. J Acquir Immune Defic Syndr 2000;24:451-7
8. McGrath JW, George K, Svilar G, Ihler E, Mafigiri D, Kabugo M. Knowledge about vaccine trials and willingness to participate in an HIV/AIDS vaccine study in the Ugandan military. J Acquir Immune Defic Syndr Hum Retrovirol 2001;27:381-8
9. Tello J, Soong SJ, Hunter B, Meriwether R, Hook EW, Mulligan MJ. HIV vaccine acceptance among heterosexual clients of a sexually transmitted diseases clinic. Am J Med Sci 1998;315:11-16
10. Jenkins RA, Torugsa K, Markowitz LE, et al. Willingness to participate in HIV-1 vaccine trials among young Thai men. Sex Transm Infect 2000;76:386-92
11. Koblin BA, Heagerty P, Sheon A, Buchbinder S, Celum C, Douglas JM. Readiness of high-risk populations in the HIV network for prevention trials to participate in HIV vaccine efficacy trials in the United States. AIDS 1998;12:785-93
12. O'Connell JM, Hogg RS, Chan K, Strathdee SA, McLean N, Martindale SL. Willingness to participate and enroll in a phase 3 preventive HIV-1 vaccine trial. J Acquir Immune Defic Syndr 2002;31:521-8